Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 50-56

  Shah, Nina ^a   Cabanillas, Fernando ^b   McIntyre, Bradley ^a   Feng, Lei ^a   McLaughlin, Peter ^a   Rodriguez, Maria A ^a   Romaguera, Jorge ^a   Younes, Anas ^a   Hagemeister, Fredrick B ^a   Kwak, Larry ^a   Fayad, Luis ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Hospital Auxilio Mutuo   (Puerto Rico)

Author keywords

Biomarkers; CD44; ICAM 1; Indolent lymphoma; VCAM 1

Indexed keywords

BETA 2 MICROGLOBULIN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS;

EID: 84855419192     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.616611     Document Type: Article

References (46)

1. A nsell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005;80:1087-1097. (Pubitemid 41099397)
2. L opez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Index for aggressive lymphomas to patients with lowgrade lymphoma. J Clin Oncol 1994;12:1343-1348.
3. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (Pubitemid 39166497)
4. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
5. D rillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000;95:1900-1910. (Pubitemid 30151624)
6. Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol 2010;22:424-430.
7. N aor D, Wallach-Dayan SB, Zahalka MA, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-267.
8. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-12164. (Pubitemid 23004805)
9. G al I, Lesley J, Ko W, et al. Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow. J Biol Chem 2003;278: 11150-11158. (Pubitemid 36792669)
10. Herrlich P, Morrison H, Sleeman J, et al. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumorsuppressing cofactor. Ann NY Acad Sci 2000;910:106 - 118; discussion 118-120.
11. Bartolazzi A, Peach R, Aruff o A, et al. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66. (Pubitemid 24181055)
12. Wielenga VJ, Heider KH, Offerhaus GJ, et al. Expression of CD44 variant proteins in human colorectal cance
13. T acyildiz N, Cavdar AO, Yavuz G, et al. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival. Pediatr Int 2001;43:354-360. (Pubitemid 32777585)
14. N iitsu N, Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin ' s lymphoma. Leuk Res 2002;26:241-248. (Pubitemid 34037020)
15. S asaki K, Niitsu N. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin ' s lymphoma. Eur J Haematol 2000;65:195-202.
16. H olland J, Owens T. Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. J Biol Chem 1997;272:9108-9112. (Pubitemid 27154914)
17. L alancette M, Aoudjit F, Potworowski EF, et al. Resistance of ICAM- 1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood 2000;95:314-319. (Pubitemid 30017258)
18. A bdelrazik N, Fouda M, Zaghloul MH, et al. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma. Med Princ Pract 2008;17:233-238. (Pubitemid 351535843)
19. S yrigos KN, Salgami E, Karayiannakis AJ, et al. Prognostic significance of soluble adhesion molecules in Hodgkin ' s disease. Anticancer Res 2004;24:1243-1247. (Pubitemid 38624969)
20. T erol MJ, Tormo M, Martinez-Climent JA, et al. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diff use large B-cell lymphoma: association with clinical characteristics and outcome. Ann Oncol 2003;14:467-474. (Pubitemid 36367427)
21. D eem TL, Abdala-Valencia H, Cook-Mills JM. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J Immunol 2007;178:3865-3873. (Pubitemid 46417656)
22. C hristiansen I, Sundstrom C, Kalkner KM, et al. Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin ' s lymphomas. Eur J Haematol 1999;62:202-209. (Pubitemid 29111488)
23. H atzistilianou M, Athanassiadou F, Agguridaki C, et al. Circulating soluble adhesion molecule levels in children with acute lymphoblastic leukaemia. Eur J Pediatr 1997;156:537-540. (Pubitemid 27289852)
24. C hristiansen I, Sundstrom C, Enblad G, et al. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin ' s disease. Br J Haematol 1998;102:701-709. (Pubitemid 28387052)
25. Loeffler-Ragg J, Germing U, Sperr WR, et al. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2011;78:150-161.
26. F abris C, Falleti E, Pirisi M, et al. Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin Chim Acta 1995;243:25-33. (Pubitemid 26024061)
27. C hen C, Chang MC, Hsieh RK, et al. Activation of CD44 facilitates DNA repair in T-cell lymphoma but has differential effects on apoptosis induced by chemotherapeutic agents and ionizing radiation. Leuk Lymphoma 2005;46:1785-1795. (Pubitemid 43203114)
28. A boul-Enein M, El-Sayed GM, El-Maghraby S, et al. Intercellular adhesion molecule-1(ICAM-1), CD44s expression and serum level of sICAM-1 in disseminated non-Hodgkin ' s lymphoma: correlation with overall survival. J Egypt Natl Canc Inst 2004;16:244-251.
29. W eekes CD, Kuszynski CA, Sharp JG. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk Lymphoma 2001;40:631-645. (Pubitemid 32303252)
30. Christiansen I, Gidlof C, Wallgren AC, et al. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 1994;84:3010-3016. (Pubitemid 24328092)
31. Perez-Encinas M, Quintas A, Bendana A, et al. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin ' s lymphoma. Leuk Lymphoma 1999;33:551-558. (Pubitemid 29213612)
32. Christiansen I, Enblad G, Kalkner KM, et al. Soluble ICAM-1 in Hodgkin ' s disease: a promising independent predictive marker for survival. Leuk Lymphoma 1995;19:243-251.
33. F ukuda Y. Clinical significance of serum CD44 measurement in malignant lymphoma. Kurume Med J 2001;48:65-69. (Pubitemid 33606574)
34. M aenpaa H, Ristamaki R, Virtamo J, et al. Serum CD44 levels preceding the diagnosis of non-Hodgkin ' s lymphoma. Leuk Lymphoma 2000;37:585-592. (Pubitemid 30219067)
35. O rian-Rousseau V. CD44, a therapeutic target for metastasizing tumours. Eur J Cancer 2010;46:1271-1277.
36. D eLisser HM. CD44: target for antiangiogenesis therapy. Blood 2009;114:5114-5115.
37. A lkhamesi NA, Ziprin P, Pfistermuller K, et al. ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis 2005;22:449-459. (Pubitemid 41750697)
38. Textor S, Accardi R, Havlova T, et al. NF-kappa B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer 2011;128:1104-1113.
39. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005;17:251-258. (Pubitemid 40692659)
40. Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, et al. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004;11:665-680. (Pubitemid 39299207)
41. Gosk S, Moos T, Gottstein C, et al. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008;1778:854-863.
42. Morito T, Fujihara M, Asaoku H, et al. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci 2009;100: 1255-1260.
43. Martin W, Abraham R, Shanafelt T, et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 2007;149:231-235. (Pubitemid 46442009)
44. I qbal J, Liu Z, Deffenbacher K, et al. Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 2009;22:191-210.
45. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diff use large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-1847.
46. Zhang MZ, Sun ZC, Fu XR, et al. Analysis of serum proteome profiles of non-Hodgkin lymphoma for biomarker identification. J Proteomics 2009;72:952-959.